Apparently, low-CAFRS patients scored higher in multiple antitumor immunity-related activities such as CD8+ T cell effector, cancer antigen presentation, trafficking and infiltration of immune cells into tumors, T-cell mediated tumor killing, chemokines, etc. than those high-CAFRS individuals, indicating that lower CAFRSs were associated with better anti-tumor immunity (Figures 9D–F). This evidence concerns the gene CD8A and cancer.